



#9

INFORMATION DISCLOSURE CITATION

OMB No. 0651-0011

RECEIVED

Atty. Docket No.	P32685	Appln. No.	09/689,483
Applicant	Storm et al.	AUG 20 2003	
Filing Date	October 12, 2000	Group:	1615

TECH CENTER 1600/2000

U.S. PATENT DOCUMENTS						
Examiner Initial*	Document Number	Issue/ Publication Date	Name	Class	Sub Class	Filing Date If Appropriate
RB	US 6,027,748	02/22/00	Conte et al.			
	US 6,090,411	07/18/00	Pillay et al.			
RB	US 2002/0099044 A1	07/25/02	Bax et al.			
FOREIGN PATENT DOCUMENTS						
	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
RB	EP 0080862A1	09/25/85	EPO			
	EP 0080862 B1	09/25/85	EPO			
	WO 01/13883 A1	03/01/01	WIPO			
	WO 02/30392 A2	04/18/02	WIPO			
	WO 02/49618 A1	06/27/02	WIPO			
RB	WO 03/17985-A1	03/06/03	WIPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
RB	Murbach et al., "Mise en évidence <i>in vitro</i> d'un véritable effet post-inhibiteur de bêta-lactamases (EPIBLA) de l'acide clavulanique sur <i>Klebsiella pneumoniae</i> et <i>Haemophilus influenzae</i> ," Path Biol, 1999, 47(5): 462-468.

Examiner	Rachel M. Bennett	Date Considered	9/3/03
*Examiner:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce		

INFORMATION DISCLOSURE CITATION
List A: References from Instant Specification

#14

Atty. Docket No.	P32685	Appln. No.	09/689,483
Applicant	Storm, et al.		
Filing Date	October 12, 2000	Group:	1615

U.S. PATENT DOCUMENTS							
Examiner Initial*		Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
AB		EP 0234670A2	09/02/87	EPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	

Examiner	<i>Rachel Bernstein</i>	Date Considered	<i>3/28/03</i>
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			
Form PTO 1449		Patent and Trademark Office - U.S. Department of Commerce	

INFORMATION DISCLOSURE CITATION

List B: References from USSN 08/993,898 and its Continuation

#14

Atty. Docket No.	P32685	Appln. No.	09/689,483
Applicant	Storm, et al.		
Filing Date	10/12/2000	Group:	1615

U.S. PATENT DOCUMENTS							
Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate	
RB	US 4,427,690	01/24/84	Cole et al.				

FOREIGN PATENT DOCUMENTS							
	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No	
RB	GB 1,508,977	04/26/78	Great Britain				
	WO 93/00898	01/21/93	WIPO				
RB	WO 96/34605	11/07/96	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
RB	Caillon et al., May 1998, "Dynamics of the bacteriophage activity of ofloxacin-amoxicillin and ofloxacin-clavulanic acid against pathogen bacteria of the respiratory tract", Pathologie Biologie, 36(5), pgs. 414-419.
	Greenwood, D., "Short Communication: a type of interaction between clavulanic acid and other β -lactam antibiotics distinct from the β -lactamase inhibition effect," from Augmentin: clavulanate-potentiated amoxycillin, Proceeding of the First Symposium, July 3-4, 1980, pages 80-83.
	Physicians' Desk Reference, 40 th Edition, 1986, "Amoxycillin," pp. 1315-1316.
	Segatore, et al., 1993, "In vitro Activity of Cefodizime (HR-221) in Combination with β -Lactamase Inhibitors," Journal of Chemotherapy, Vol. 5, No. 3, pp. 147-150.
RB	Sumita et al., 1991, "In vitro Synergistic Activity between Meropenem and other Beta-Lactams against Methicillin-Resistant <i>Staphylococcus aureus</i> ," European Journal of Clinical Microbiology and Infectious Diseases, Vol. 10, No. 2, pp. 77-84.

Examiner	Richard Burnett	Date Considered	3/28/03
*Examiner:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		
Form PTO 1449		Patent and Trademark Office - U.S. Department of Commerce	

OMB No. 0651-0011

INFORMATION DISCLOSURE CITATION
List C: References from USSN 09/544,019

#14

Atty. Docket No. P32685	Appln. No. 09/689,483
Applicant Storm, et al.	
Filing Date 10/12/2000	Group: 1615

U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
RB	US2002/0064562	05/30/02	Martin et al.			
	US2002/0086056	07/04/02	Grimmett et al.			
	US 5,690,959	11/25/97	Palepu et al.			
	US 5,851,550	12/22/98	Martin et al.			
	US 5,861,172	01/19/99	Martin et al.			
	US 5,910,322	06/08/99	Rivett et al.			
	US 6,110,497	08/29/00	Martin et al.			
	US 6,136,345	10/24/00	Grimmett et al.			
	US 6,299,903 B1	10/09/01	Rivett et al.			
	US 6,352,720 B1	03/05/02	Martin et al.			
RB	US 6,358,528 B1	03/19/02	Grimmett et al.			

FOREIGN PATENT DOCUMENTS

Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

RB	Remington's Pharmaceutical Sciences, Eighteenth Edition, 1990, pp. 1304-1308, 1317-1323

Examiner Rachel Bruntz	Date Considered 2/28/03
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449 Patent and Trademark Office - U.S. Department of Commerce	

INFORMATION DISCLOSURE CITATION

List D: References from Chart Summarizing Copending Applications #14

Atty. Docket No.	P32685	Appln. No.	09/689,483
Applicant	Storm, et al.		
Filing Date	October 12, 2000	Group:	1615

U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
RB	US 5,670,170	09/23/97	Grimmett et al.			
	US 6,214,359 B1	04/10/01	Bax			
	US 6,294,199 B1	09/25/01	Conley et al.			
RB	US 6,399,086 B1	06/04/02	Katzhendler et al.			

FOREIGN PATENT DOCUMENTS

	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
RB	EP 0131147B2	12/04/96	EPO			
	WO 95/20946	08/10/95	WIPO			
	WO 95/28927	11/02/95	WIPO			
	WO 97/09042	03/13/97	WIPO			
	WO 98/22091	05/28/98	WIPO			
RB	GB 1,508,977	04/26/78	Great Britain			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

RB	Remington's Pharmaceutical Sciences, Eighteenth Edition, 1990, pp. 1304-1308, 1317-1323
----	---

Examiner	<i>Richard Q. Bennett</i>	Date Considered	3/28/03
*Examiner:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		
Form PTO 1449		Patent and Trademark Office - U.S. Department of Commerce	

INFORMATION DISCLOSURE CITATION

List E: Documents from Response filed November 22, 2002 and Response in 09/971,560 #14

Atty. Docket No.	P32685	Appln. No.	09/689,483
Applicant	Storm et al.		
Filing Date	October 12, 2000	Group:	1615

U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
EB	US 2001/0038838 A1	Nov. 8, 2001	Burch			
	US 2001/0043926 A1	Nov. 22, 2001	Burch			
	4,303,582	Dec. 1, 1981	Shean et al.			
	5,225,197	Jul. 6, 1993	Bolt et al.			
	5,670,170	Sep. 23, 1997	Grimmett et al.			
	5,814,337	Sep. 29, 1998	Merrifield et al.			
	6,051,254	Apr. 18, 2000	Merrifield et al.			
	6,051,255	Apr. 18, 2000	Conley et al.			
EB	6,077,536	Jun. 20, 2000	Merrifield et al.			

FOREIGN PATENT DOCUMENTS

	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
EB	WO 93/00898	Jan. 21, 1993	WIPO			
EB	WO 96/34605	Nov. 7, 1996	WIPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

--

Examiner:	Date Considered: 3/28/03
-----------	--------------------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

List G: Miscellaneous Documents

#14

Atty. Docket No. P32685	Appln. No. 09/689,483
Applicant Storm et al.	
Filing Date October 12, 2000	Group: 1615

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
RB	US 5,077,790	04/16/91	Shell			
	US 5,582,837	12/10/96	Shell			
	US 5,972,389	10/26/99	Shell et al.			
RB	US 6,340,475 B2	01/22/02	Shell et al.			

FOREIGN PATENT DOCUMENTS

Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

--

Examiner <i>Rachel Bennett</i>	Date Considered <i>3/28/03</i>

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

List F: Litigation References

#14

Atty. Docket No.	P32685	Appln. No.	09/689,483
Applicant	Storm et al.		
Filing Date	October 12, 2000	Group:	Not Yet Assigned

U.S. PATENT DOCUMENTS							
Examiner Initial*		Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Geneva Pharmaceuticals, Inc., et al. v. GlaxoSmithKline PLC, et al.: The Opinion and Order rendered on July 19, 2002 (as issued by the court)
	Geneva Pharmaceuticals, Inc., et al. v. GlaxoSmithKline PLC, et al.: The Opinion and Order rendered on July 19, 2002 (as published by West Law at 2002 WL 1802991)
	Geneva Pharmaceuticals, Inc., et al. v. GlaxoSmithKline PLC, et al.: The trial transcript of May 23, 2002 relating to the Court's decision of July 19, 2002
	Geneva Pharmaceuticals, Inc., et al. v. GlaxoSmithKline PLC, et al.: The Opinion and Order rendered April 22, 2002
	Geneva Pharmaceuticals, Inc., et al. v. GlaxoSmithKline PLC, et al.: the trial transcript of March 13, 2002, relating to the Court's decision of April 22, 2002
	Geneva Pharmaceuticals, Inc., et al. v. GlaxoSmithKline PLC, et al.: the Opinion and Order rendered February 25, 2002
	Geneva Pharmaceuticals, Inc., et al. v. GlaxoSmithKline PLC, et al.: the trial transcript of December 14, 2001 relating to the Court's decision of February 25, 2002

Examiner	<i>Lach Q. Bennett</i>	Date Considered	<i>2/16/06</i> <i>3/28/03</i>
*Examiner:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		
Form PTO 1449		Patent and Trademark Office - U.S. Department of Commerce	

OMB No. 0651-0011

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	P32685	Appl. No.	09/889,483
Applicant	Storm et al.		
Filing Date	October 12, 2000	Group:	1615

U.S. PATENT DOCUMENTS						
Examiner Initials	Document Number	Issue Date	Name	Class	Sub Class	Filing Date if Appropriate
	USSN 09/544,040		Conley et al.			April 6, 2000
	USSN 10/115,700		Conley et al.			April 4, 2002
M	U.S. Pat 6,294,199	September 25, 2001	Conley et al.			
	USSN 09/811,805		Conley et al.			July 24, 2001
	USSN 09/871,660		Conley et al.			October 5, 2001
	USSN 09/874,396		Storm et al.			October 10, 2001
	USSN 09/874,392		Storm et al.			October 10, 2001

FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	

Examiner	<i>Neil Cuy</i>	Date Considered	<i>2/5/06</i>
*Examiner:	Initial if reference considered, whether or not citation is in conformance with MPEP 608; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		
Form PTO 1449		Patent and Trademark Office - U.S. Department of Commerce	

* ALL considered, but NOT TO be printed, so lined out.